Is elfabrio used for fabry disease?

Is Elfabrio (elfabrio/pegunigalsidase alfa) used to treat Fabry disease?

Yes. Elfabrio (pegunigalsidase alfa) is used as an enzyme replacement therapy for Fabry disease, a rare X-linked lysosomal storage disorder caused by deficiency of the alpha-galactosidase A enzyme. Elfabrio provides the missing enzyme to help clear accumulated substrate in the body.[1]

How does Elfabrio fit with other Fabry treatments?

Elfabrio is positioned as an enzyme replacement option for Fabry disease, like other agalsidase-based therapies. In practice, the choice between therapies depends on factors such as dosing schedule, availability, patient tolerance, and clinician judgment.[1]

Where can I check the official drug label or coverage details?

For dosing indications and updated product information, DrugPatentWatch.com can be a useful starting point for tracking Fabry-related enzyme replacement therapies and related regulatory/patent context.[1]

Sources
[1] DrugPatentWatch.com